Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 70
Filtrar
1.
Vet Rec ; 157(12): 347-9, 2005 Sep 17.
Artigo em Inglês | MEDLINE | ID: mdl-16170003

RESUMO

A three-year-old cat with lymphadenopathy, non-regenerative anaemia and marked leucocytosis (171.3 x 10(9) white blood cells/l) was diagnosed with monocytic leukaemia and treated with a combination of anticancer drugs. A number of mature and immature monocyte-like cells were detected in the peripheral blood and bone marrow; they proved to be monocytic cells by cytochemical examination and an analysis of their cell surface phenotype, indicating that the cat suffered from acute myeloid leukaemia, subclassified as monocytic leukaemia (M5). Treatment with cytarabine, doxorubicin, vincristine and prednisolone greatly reduced the number of blast cells in the cat's peripheral blood and bone marrow. The cat was in partial remission for 67 days and survived for 95 days after it was first examined.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Doenças do Gato/diagnóstico , Leucemia Monocítica Aguda/veterinária , Animais , Doenças do Gato/tratamento farmacológico , Gatos , Evolução Fatal , Feminino , Leucemia Monocítica Aguda/diagnóstico , Leucemia Monocítica Aguda/tratamento farmacológico , Prognóstico , Indução de Remissão
2.
Res Vet Sci ; 78(2): 151-4, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15563922

RESUMO

Molecularly cloned feline leukemia virus (FeLV)-clone 33 (C-33), derived from a cat with acute myelocytic leukemia (AML), was examined to assess its relation to the pathogenesis of AML and myelodysplastic syndrome (MDS). To evaluate in vitro pathogenicity of FeLV C-33, bone marrow colony-forming assay was performed on marrow cells infected with FeLV C-33 or an FeLV subgroup A strain (61E, a molecularly cloned strain with minimal pathogenicity). The myeloid colony-forming activity of feline bone marrow mononuclear cells infected with FeLV C-33 was significantly lower than that of cells infected with 61E. This suggests that FeLV C-33 has myeloid lineage-specific pathogenicity for cats, and that FeLV C-33 infection is useful as an experimental model for investigating pathogenesis of MDS and AML.


Assuntos
Doenças do Gato/virologia , Vírus da Leucemia Felina/genética , Vírus da Leucemia Felina/patogenicidade , Leucemia Mieloide Aguda/veterinária , Células Progenitoras Mieloides/virologia , Infecções por Retroviridae/veterinária , Sequências Repetidas Terminais , Infecções Tumorais por Vírus/veterinária , Animais , Células da Medula Óssea/citologia , Células da Medula Óssea/virologia , Gatos , Clonagem Molecular , DNA Viral/química , DNA Viral/genética , Leucemia Mieloide Aguda/patologia , Leucemia Mieloide Aguda/virologia , Síndromes Mielodisplásicas/veterinária , Síndromes Mielodisplásicas/virologia , Células Progenitoras Mieloides/citologia , Reação em Cadeia da Polimerase/veterinária , Infecções por Retroviridae/virologia , Infecções Tumorais por Vírus/virologia
5.
Tokai J Exp Clin Med ; 26(1): 19-24, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11592298

RESUMO

Tsutsugamushi disease is characterized by the early appearance of a black crust at the bitten area and the subsequent development of macular or macropapular rush on the whole body with high fever. While treatment with tetracycline derivatives and chloramphenicols is effective, delayed diagnosis or inappropriate treatment will lead to fatality. In this report, we describe two typical cases of tsutsugamushi disease and discuss other incidences in Kanagawa Prefecture, Japan, in 1998. One of the present two patients was diagnosed to be a case of the new type by Kawasaki strain of Rickettsia tsutsugamushi, while responsible strain was not identified for the other case. Since the disease is spreading widely even to suburban areas, we emphasize the need to consider the possible diagnosis of tsutsugamushi disease in patients with generalized eruption and high fever.


Assuntos
Tifo por Ácaros/epidemiologia , Antibacterianos/uso terapêutico , Feminino , Humanos , Incidência , Japão/epidemiologia , Pessoa de Meia-Idade , Minociclina/uso terapêutico , Vigilância da População , Tifo por Ácaros/tratamento farmacológico , Tifo por Ácaros/patologia , Tifo por Ácaros/fisiopatologia , Resultado do Tratamento
6.
Transplantation ; 72(3): 422-7, 2001 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-11502970

RESUMO

BACKGROUND: Immunosuppression involves the nature of the immunosuppressive agents and individual differences in patient factors. We investigated whether the effect of mycophenolate mofetil (MMF) is measurable using an in vitro measure of immunocompetence and related its effects to cyclosporine (CsA) in vitro. METHODS: Liver or kidney transplant recipients receiving prednisone; CsA or tacrolimus; and MMF, azathioprine (AZA), or neither, were studied. Immunocompetence was assessed by one-way mixed lymphocyte culture using patients' peripheral blood leukocytes (PBL) and three validated stimulators. The effect of immunosuppressive agents added in vitro on normal PBL stimulation by Staphylococcus enterotoxin B was determined by the carboxyfluorescein diacetate succinimidyl ester measurement of division. RESULTS: Patients receiving MMF had an average immunocompetence level of 12+/-23, compared with 39.7+/-65 and 25.5+/-42 for those receiving AZA or neither AZA nor MMF, respectively. Thus, there was an approximately 80% suppression of the response in the MMF group. Assessment of normal cell division revealed that CsA allowed multiple cell generations but suppressed the numbers of cells in each, whereas MMF blocked proliferation into subsequent generations. Addition of clinically relevant levels of mycophenolic acid, the active agent for MMF, added to more moderate levels of CsA, was required to achieve greater than 80% suppression, consistent with the degree of immunocompetence depression measured in patients. CONCLUSIONS: These data provide the novel finding that the effect of MMF treatment on patients is measurable in their PBL as decreased immunocompetence in vitro. The effect of MMF on normal PBL approximates the 80% inhibition that we found in patients. Moreover, the effect of MMF on cell division provides a rationale for the superior effectiveness of regimens including MMF.


Assuntos
Imunossupressores/uso terapêutico , Transplante de Rim , Transplante de Fígado , Ácido Micofenólico/uso terapêutico , Azatioprina/uso terapêutico , Divisão Celular/efeitos dos fármacos , Células Cultivadas , Ciclosporina/farmacologia , Ciclosporina/uso terapêutico , Combinação de Medicamentos , Enterotoxinas/farmacologia , Humanos , Imunocompetência/efeitos dos fármacos , Imunossupressores/farmacologia , Rim/patologia , Fígado/patologia , Linfócitos/efeitos dos fármacos , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/farmacologia , Valores de Referência
9.
Clin Transplant ; 15(2): 111-5, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11264637

RESUMO

Several studies indicate that the poorer outcomes for African--Americans after transplantation may be due to decreased effectiveness of immunosuppressive agents. Using an in vitro test of immunocompetence (IMC), we measured the effects of immunosuppression on African-American, compared with Caucasian, kidney or liver transplantation recipients. The IMC result was the highest of three mixed lymphocyte culture responses using validated stimulator cell pools. A total of 293 tests were done in Caucasians and 144 in African--Americans. Overall, the IMC for African--Americans was 38, compared with 19 for Caucasians (p<0.01). This decreased effect of immunosuppression (higher IMC) was the same for liver as for kidney transplant recipients, occurred at the 2--3-yr interval, and was largely in patients of tacrolimus (FK506), with a strong but not significant trend in cyclosporine (CYA) recipients. The two groups were on the same nominal immunosuppression and FK506 and CYA levels were not different. We conclude that African-Americans retain more immune responsiveness on equivalent dose immunosuppression, notable particularly in years 2--3 after transplantation when earlier graft loss occurs in this group.


Assuntos
População Negra , Imunocompetência/efeitos dos fármacos , Imunossupressores/farmacologia , Transplante de Rim/imunologia , Transplante de Fígado/imunologia , Negro ou Afro-Americano , Ciclosporina/farmacologia , Humanos , Teste de Cultura Mista de Linfócitos , Tacrolimo/farmacologia , Fatores de Tempo , População Branca
12.
Anticancer Res ; 20(6A): 4097-102, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11131678

RESUMO

BACKGROUND: Vascular endothelial growth factor (VEGF) is thought to be the most potent angiogenic factor in the numerous malignant tumors and a prognostic indicator for cancer patients. Interleukin 12 (IL-12) is a heterodimeric cytokine that has potent anti-tumor and anti-metastatic activities. Recently, it has been suggested that IL-12 regulates VEGF in a murine breast cancer model. MATERIALS AND METHODS: Blood from 26 patients with colorectal cancer was obtained prior to surgery. Plasma levels of VEGF and serum levels of IL-12 were assessed using the quantitative sandwich enzyme immunoassay technique. We investigated the preoperative relationships between plasma levels of VEGF, serum levels of IL-12 and clinicopathological factors in patients with colorectal cancer. RESULTS: Although not statistically significantly, high plasma levels of VEGF and low serum levels of IL-12 tended to occur with more advanced colorectal cancer. Plasma levels of VEGF in patients who had circumferential involvement of the tumor greater than 1/2 were only significantly increased. The preoperative relationship between plasma levels of VEGF and serum levels of IL-12 tended to be negatively correlated. CONCLUSION: These results suggest that high plasma levels of IL-12 or low serum levels of IL-12 may be observed in more advanced colorectal cancer patients. Thus, these patients may require additional immunochemotherapy after surgery. IL-12 may regulate VEGF in the patients diagnosed with colorectal cancer.


Assuntos
Biomarcadores Tumorais/sangue , Neoplasias Colorretais/sangue , Fatores de Crescimento Endotelial/sangue , Interleucina-12/sangue , Linfocinas/sangue , Adulto , Idoso , Neoplasias Colorretais/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio Vascular
14.
Chem Pharm Bull (Tokyo) ; 48(5): 708-15, 2000 May.
Artigo em Inglês | MEDLINE | ID: mdl-10823710

RESUMO

Aspartame (L-alpha-aspartyl-L-phenylalanine methyl ester) is a dipeptide sweetener about 200 times as sweet as sugar. It exists in crystal forms such as IA, IB, IIA, and IIB, which differ in crystal structure and in the degree of hydration. Among these, IIA is the most stable crystal form, and its crystal structure has been well determined (Hatada et al., J. Am. Chem. Soc., 107, 4279-4282 (1985)). To elucidate the structural factors of thermal stability in the IIA form of aspartame and to examine the physical process in the crystal transformation between the IIA and IIB forms, we performed a thermal analysis and solid-state NMR measurements. We found that a quasi-stable intermediate state exists in the transformation, and it has the same crystal lattice as the usual IIA form, despite the dehydration from 1/2 mol to 1/3 mol per 1 mol of aspartame. The results of the energy component analysis and the molecular dynamics simulation suggest that the entropic effect promotes the generation of the intermediate state, which is presumably caused by the evaporation of the water of crystallization and the increase of molecular motion in aspartame. Thus, the thermal stability of the IIA form is attributable to a structural property, i.e., the crystal lattice itself is retained during the above dehydration. Moreover, the molecular dynamics simulations suggest that the aspartame molecules have two kinds of conformational flexibility in the intermediate state.


Assuntos
Aspartame/química , Cristalização , Cristalografia por Raios X , Análise Diferencial Térmica , Ligação de Hidrogênio , Espectroscopia de Ressonância Magnética , Conformação Molecular , Termogravimetria
15.
Am J Surg ; 179(1): 42-5, 2000 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-10737577

RESUMO

BACKGROUND: Homologous blood transfusion (HBT) has the risk of an immunosuppressive effect and may adversely affect the prognosis of patients with carcinomas. Autologous blood transfusion (ABT) has not yet become a standard procedure in gastroenteric cancer surgery. We investigated the usefulness and problems of ABT combined with the use of recombinant human erythropoietin (rh-EPO). METHODS: An evaluation of autologous blood transfusion (ABT) combined with recombinant human erythropoietin (rh-EPO) treatment was conducted in 46 patients with hepatocellular carcinoma undergoing hepatectomy. Preoperative autologous blood donation (ABD) was accomplished for 25 of the 46 patients. The preoperative changes in hemoglobin and hematocrit in relation to route of administration of erythropoietin were studied. In addition, intraoperative blood requirements and the postoperative complications for patients who predonated were compared with those of patients who underwent surgery without autologous predonation. RESULTS: The proportion of patients not requiring additional homologous blood transfusions (HBT) during operation was significantly higher in the ABD group than in the non-ABD group (88% versus 38%). The incidence of postoperative complications was significantly higher in patients receiving HBT than in nontransfused patients and in those receiving ABT. CONCLUSIONS: Preoperative autologous blood donation in combination with rh-EPO therapy markedly reduced the requirement for homologous blood transfusion during surgery in patients with hepatocellular carcinoma having hepatectomy.


Assuntos
Transfusão de Sangue Autóloga , Carcinoma Hepatocelular/cirurgia , Hepatectomia , Neoplasias Hepáticas/cirurgia , Estudos de Casos e Controles , Eritropoetina/uso terapêutico , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/epidemiologia , Proteínas Recombinantes
19.
Masui ; 45(9): 1153-9, 1996 Sep.
Artigo em Japonês | MEDLINE | ID: mdl-8905955

RESUMO

Forty-five patients scheduled for intra-abdominal gynecological surgeries, ranging in age from 30 to 60 years, were anesthetized with combined spinal-epidural (CSE) method using combined spinal-epidural needles inserted at the L2-3 interspace. Ten minutes after intrathecal administration of 0.4% isobaric tetracaine solution (2.5 ml) the upper level of analgesia was examined by pin prick method and the patients were divided into the group A (N = 7; anesthetic level > or = Th7), B (N = 7; Th8-10) and C (N = 31; Th11-L1) according to their anesthetic levels. Target anesthetic level (Th4-7) was obtained in group B by peridural administration of 2% mepivacaine in a dose of 5 ml and the surgery was performed. However, in group C, mepivacaine 7 ml was insufficient to obtain the target anesthetic level and additional mepivacaine was necessary for the surgery. In group A, no mepivacaine was used in the first hour of the surgery. In all patients, except one in group C, in whom general anesthesia was used after insufficient segmental analgesia, anesthesia was maintained by the CSE technique. We concluded that adequate anesthetic level for the intra-abdominal surgery can be obtained by intrathecal isobaric tetracaine administration combined with peridural mepivacaine of a dose calculated according to the anesthetic level ten minutes after the spinal block.


Assuntos
Anestesia Epidural , Anestesia Obstétrica , Raquianestesia , Anestésicos Combinados , Anestésicos Locais , Mepivacaína , Tetracaína , Adulto , Anestésicos Combinados/administração & dosagem , Anestésicos Locais/administração & dosagem , Feminino , Doenças dos Genitais Femininos/cirurgia , Humanos , Mepivacaína/administração & dosagem , Pessoa de Meia-Idade , Tetracaína/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA